This is the authors' abstract. We don't add key points for this paper.
The identification of noninvasive biomarkers is still one of the major issue for gastroenterologists dealing with inflammatory bowel disease patients, due to the chronicity of these conditions and the early onset of symptoms in the majority of cases. Research attention has focused mainly on fecal proteins, especially calprotectin and lactoferrin, and most of the published data are reassuring about their applicability in the diagnosis and monitoring of these patients. However, there are still pending questions regarding the reliability of fecal proteins especially in the era of mucosal healing and biologics.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Caccaro et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: